Skip to main content
Top
Published in: Pathology & Oncology Research 3/2011

01-09-2011 | Research

Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma

Authors: Naoki Matsumoto, Takashi Umezawa, Toru Sasaki, Kuninobu Nakajima, Yukiko Kanetsuna, Hiroshi Sasaki

Published in: Pathology & Oncology Research | Issue 3/2011

Login to get access

Abstract

In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognostic value of IGNCs in pT1 OCCC. Eighty-seven pT1 OCCC patients who underwent initial surgery at Jikei University Kashiwa Hospital, Chiba, Japan, were retrospectively assessed. Paraffin-embedded tissue sections (PTSs) stained with hematoxylin and eosin were reviewed. Giant nuclear cells (GNCs) were defined as cells with a nuclear length of more than twice the median nuclear length. GNCs with irregular nuclear circumferences were defined as IGNCs. Cases where one or more GNCs existed and where IGNCs accounted for >10% of the GNCs were classified as IGNC-positive. We also attempted to identify IGNCs on touch imprint cytology smears (TICSs). Among the 87 cases, 68 were IGNC-negative and 19 were IGNC-positive. The 5-year disease-free and overall survival rates were 88.9% and 90.3% in the total patients, 98.3% and 100% in the IGNC-negative group, and 59.7% and 62.0% in the IGNC-positive group, respectively. These survival rates were significantly lower in the IGNC-positive group than in the IGNC-negative group (adjusted hazard ratio = 14, 95% confidence interval = 2.7–124 and adjusted hazard ratio = 25, 95% confidence interval = 2.9–768, respectively). Prognostic differences were not identified for other factors. IGNC identification on 28 available TICSs predicted IGNC identification on PTSs (sensitivity = 50.0%, specificity = 100%, P = 0.007). The presence of IGNCs has clinical and prognostic value for pT1 OCCC.
Literature
1.
go back to reference Serov SF, Scully RE, Sobin LH (1973) Histological typing of ovarian tumors. In: International histological classification of tumors, no.9. Geneva: World Health Organization, p37–42 Serov SF, Scully RE, Sobin LH (1973) Histological typing of ovarian tumors. In: International histological classification of tumors, no.9. Geneva: World Health Organization, p37–42
2.
go back to reference Chan JK, Teoh D, Hu JM et al (2008) Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109:370–376PubMedCrossRef Chan JK, Teoh D, Hu JM et al (2008) Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109:370–376PubMedCrossRef
3.
go back to reference Konishi I (2008) Gynecologic oncology committee report [written in Japanese]. Acta Obstet Gynaecol Jpn 60:1001–1085 Konishi I (2008) Gynecologic oncology committee report [written in Japanese]. Acta Obstet Gynaecol Jpn 60:1001–1085
4.
go back to reference Lee KR, Tavassoli FA, Prat J et al (2003) Surface epithelial-stromal tumors. In: Tavassoli FA, Devilee P (eds) WHO classification of tumours. IARC, Lyon, pp 117–145 Lee KR, Tavassoli FA, Prat J et al (2003) Surface epithelial-stromal tumors. In: Tavassoli FA, Devilee P (eds) WHO classification of tumours. IARC, Lyon, pp 117–145
5.
go back to reference Liu CQ, Sasaki H, Fahey MT et al (1999) Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma. Br J Cancer 79:1736–1741PubMedCrossRef Liu CQ, Sasaki H, Fahey MT et al (1999) Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma. Br J Cancer 79:1736–1741PubMedCrossRef
6.
go back to reference Young RC, Walton LA, Ellenberg SS et al (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322:1021–1027PubMedCrossRef Young RC, Walton LA, Ellenberg SS et al (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322:1021–1027PubMedCrossRef
7.
go back to reference Trimbos JB, Schueler JA, van der Burg M et al (1991) Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer. Cancer 67:597–602PubMedCrossRef Trimbos JB, Schueler JA, van der Burg M et al (1991) Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer. Cancer 67:597–602PubMedCrossRef
8.
go back to reference Monga M, Carmichael JA, Shelley WE et al (1991) Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecol Oncol 43:195–197PubMedCrossRef Monga M, Carmichael JA, Shelley WE et al (1991) Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecol Oncol 43:195–197PubMedCrossRef
9.
go back to reference Acta Obstet Gynecol Scand (1971) Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 50:1–7 Acta Obstet Gynecol Scand (1971) Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 50:1–7
10.
go back to reference Silverberg SG (2000) Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19:7–15PubMedCrossRef Silverberg SG (2000) Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19:7–15PubMedCrossRef
11.
go back to reference Malpica A (2008) Grading of ovarian cancer: a histotype-specific approach. Int J Gynecol Pathol 27:175–181PubMed Malpica A (2008) Grading of ovarian cancer: a histotype-specific approach. Int J Gynecol Pathol 27:175–181PubMed
12.
go back to reference Bookman MA, Greer BE, Ozols RF (2003) Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer 13:735–740PubMedCrossRef Bookman MA, Greer BE, Ozols RF (2003) Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer 13:735–740PubMedCrossRef
13.
go back to reference Utsunomiya H, Akahira J, Tanno S et al (2006) Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer 16:52–56PubMedCrossRef Utsunomiya H, Akahira J, Tanno S et al (2006) Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer 16:52–56PubMedCrossRef
14.
go back to reference Sirichaisutdhikorn D, Suprasert P, Khunamornpong S (2009) Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin. Asian Pac J Cancer Prev 10:1041–1045PubMed Sirichaisutdhikorn D, Suprasert P, Khunamornpong S (2009) Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin. Asian Pac J Cancer Prev 10:1041–1045PubMed
15.
go back to reference Sugiyama T, Kamura T, Kigawa J et al (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584–2589PubMedCrossRef Sugiyama T, Kamura T, Kigawa J et al (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88:2584–2589PubMedCrossRef
16.
go back to reference Maggioni A, Benedetti PP, Dell’Anna T et al (2006) Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 95:699–704PubMedCrossRef Maggioni A, Benedetti PP, Dell’Anna T et al (2006) Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 95:699–704PubMedCrossRef
17.
go back to reference Chan JK, Munro EG, Cheung MK et al (2007) Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 109:12–19PubMedCrossRef Chan JK, Munro EG, Cheung MK et al (2007) Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 109:12–19PubMedCrossRef
18.
go back to reference Suzuki S, Kajiyama H, Shibata K et al (2008) Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? Ann Oncol 19:1284–1287PubMedCrossRef Suzuki S, Kajiyama H, Shibata K et al (2008) Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? Ann Oncol 19:1284–1287PubMedCrossRef
19.
go back to reference Sakuragi N, Yamada H, Oikawa M et al (2000) Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0). Gynecol Oncol 79:251–255PubMedCrossRef Sakuragi N, Yamada H, Oikawa M et al (2000) Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0). Gynecol Oncol 79:251–255PubMedCrossRef
20.
go back to reference Takano M, Kikuchi Y, Yaegashi N et al (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94:1369–1374PubMedCrossRef Takano M, Kikuchi Y, Yaegashi N et al (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94:1369–1374PubMedCrossRef
21.
go back to reference Ushijima K (2007) Management of retroperitoneal lymph nodes in the treatment of ovarian cancer. Int J Clin Oncol 12:181–186PubMedCrossRef Ushijima K (2007) Management of retroperitoneal lymph nodes in the treatment of ovarian cancer. Int J Clin Oncol 12:181–186PubMedCrossRef
22.
go back to reference Geomini P, Bremer G, Kruitwagen R et al (2005) Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a meta-analysis. Gynecol Oncol 96:1–9PubMedCrossRef Geomini P, Bremer G, Kruitwagen R et al (2005) Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a meta-analysis. Gynecol Oncol 96:1–9PubMedCrossRef
23.
go back to reference Stewart CJ, Brennan BA, Hammond IG et al (2008) Intraoperative assessment of clear cell carcinoma of the ovary. Int J Gynecol Pathol 27:475–482PubMedCrossRef Stewart CJ, Brennan BA, Hammond IG et al (2008) Intraoperative assessment of clear cell carcinoma of the ovary. Int J Gynecol Pathol 27:475–482PubMedCrossRef
24.
go back to reference Vrdoljak-Mozetic D, Stanković T, Krasević M et al (2006) Intraoperative cytology of clear cell carcinoma of the ovary. Cytopathology 17:390–395PubMedCrossRef Vrdoljak-Mozetic D, Stanković T, Krasević M et al (2006) Intraoperative cytology of clear cell carcinoma of the ovary. Cytopathology 17:390–395PubMedCrossRef
25.
go back to reference Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663PubMedCrossRef Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663PubMedCrossRef
26.
go back to reference Ficarra V, Martignoni G, Maffei N et al (2005) Original and reviewed nuclear grading according to the Fuhrman system. Cancer 103:68–75PubMedCrossRef Ficarra V, Martignoni G, Maffei N et al (2005) Original and reviewed nuclear grading according to the Fuhrman system. Cancer 103:68–75PubMedCrossRef
27.
go back to reference Rioux-Leclercq N, Karakiewicz PI, Trinh QD et al (2007) Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer 109:868–874PubMedCrossRef Rioux-Leclercq N, Karakiewicz PI, Trinh QD et al (2007) Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer 109:868–874PubMedCrossRef
28.
go back to reference Novara G, Martignoni G, Artibani W et al (2007) Grading systems in renal cell carcinoma. J Urol 177:430–436PubMedCrossRef Novara G, Martignoni G, Artibani W et al (2007) Grading systems in renal cell carcinoma. J Urol 177:430–436PubMedCrossRef
Metadata
Title
Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma
Authors
Naoki Matsumoto
Takashi Umezawa
Toru Sasaki
Kuninobu Nakajima
Yukiko Kanetsuna
Hiroshi Sasaki
Publication date
01-09-2011
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-010-9356-5

Other articles of this Issue 3/2011

Pathology & Oncology Research 3/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine